• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Helix BioMedix Inc

  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Disease Focus
    • DNA Damage Response (DDR)
    • Xeroderma Pigmentosum
  • Programs
    • Pharma
    • Personal Care
  • News
    • Press Releases
    • Presentations
    • Scientific Publications
  • Investors
    • Stock Information
    • IR Updates
    • Proxy
    • Corporate Governance
  • Contact Page
You are here: Home / Investors / Proxy

Proxy

Graph with blue lines and trend.

2024 Annual Shareholders Meeting
August 21, 2024 7:00am Local Time
Courtyard by Marriott
11215 NE 124th ST, Kirkland, WA 98034

Proxy Information

Stockholder Letter July 2024 [PDF]
Proxy Combo 2024 [PDF]

Helix BioMedix, Inc. is pleased to offer the following online services:

Online Access to Proxy Statement
Our proxy materials were mailed on or about July 12, 2024 to all stockholders of record as of June 28, 2024. For your convenience, these materials may also be viewed by clicking this link https://central.proxyvote.com/pv/web

Electronic Proxy Voting
Your proxy card includes detailed instructions on how to vote via the internet. Before you vote, carefully review the proxy statement mailed on or about July 12, 2024, along with a letter to stockholders.  For your convenience, these materials may also be viewed by clicking this link https://central.proxyvote.com/pv/web

Primary Sidebar

Footer

COMPANY PROFILE

Helix BioMedix is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum.  Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body’s innate immunity.

 

 

 

 

Terms & Conditions | Privacy Policy

Search

 

©2023 HELIX BIOMEDIX, INC.
ALL RIGHTS RESERVED

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2025 · Executive Pro On Genesis Framework · WordPress · Log in